Brad H. Rovin

Active 1989–2025

182
Papers
33,266
Citations
89
h-index
174
i10-index

Citations

Citations per year for Brad H. Rovin1960: 1 citations1980: 1 citations1981: 1 citations1984: 1 citations1986: 1 citations1989: 1 citations1991: 2 citations1992: 3 citations1993: 7 citations1994: 15 citations1995: 10 citations1996: 19 citations1997: 24 citations1998: 27 citations1999: 28 citations2000: 35 citations2001: 32 citations2002: 27 citations2003: 29 citations2004: 50 citations2005: 74 citations2006: 90 citations2007: 117 citations2008: 139 citations2009: 138 citations2010: 126 citations2011: 100 citations2012: 118 citations2013: 141 citations2014: 102 citations2015: 172 citations2016: 181 citations2017: 145 citations2018: 152 citations2019: 663 citations2020: 806 citations2021: 1,002 citations2022: 1,115 citations2023: 1,148 citations2024: 2,030 citations2025: 1,045 citations2026: 21 citations1961–1979: no citations, so these years are not shown1982–1983: no citations, so these years are not shown1985: no citations, so this year is not shown1987–1988: no citations, so these years are not shown1990: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,716 citing papers, 23.2% of this breakdownChina: 1,357 citing papers, 11.6% of this breakdownUnited Kingdom: 843 citing papers, 7.2% of this breakdownGermany: 622 citing papers, 5.3% of this breakdownItaly: 595 citing papers, 5.1% of this breakdownFrance: 427 citing papers, 3.6% of this breakdownCanada: 425 citing papers, 3.6% of this breakdownJapan: 416 citing papers, 3.6% of this breakdownSpain: 364 citing papers, 3.1% of this breakdownNetherlands: 353 citing papers, 3% of this breakdownAustralia: 322 citing papers, 2.8% of this breakdownSweden: 227 citing papers, 1.9% of this breakdown
0%23.2%Other 26%

Fields

  • Medicine72%
  • Biochemistry, Genetics and Molecular Biology15.7%
  • Immunology and Microbiology7.6%
  • Neuroscience0.8%
  • Agricultural and Biological Sciences0.6%
  • Engineering0.5%
  • Other2.8%

Topics

  • Renal Diseases and Glomerulopathies8%
  • Systemic Lupus Erythematosus Research7.1%
  • Chronic Kidney Disease and Diabetes5.7%
  • Vasculitis and related conditions3%
  • T-cell and B-cell Immunology2%
  • Dialysis and Renal Disease Management1.8%
  • Other72.4%

Coauthors

All papers

Open in search
  1. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Kidney International 2021 cited by 2,416

  2. An atlas of healthy and injured cell states and niches in the human kidney

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sylvia E. Rosas, F. Perry Wilson, Paul M. Palevsky, Krzysztof Kiryluk, John R. Sedor, Robert D. Toto, Chirag R. Parikh, Eric H. Kim, Rahul Satija, Anna Greka, Evan Z. Macosko, Peter V. Kharchenko, Joseph P. Gaut, Jeffrey B. Hodgin, Richard A. Knight, Stewart H. Lecker, Isaac E. Stillman, Afolarin Amodu, Titlayo Ilori, Shana Maikhor, Insa M. Schmidt, Gearoid M. McMahon, Astrid Weins, Nir Hacohen, Lakeshia Bush, Agustin Gonzalez‐Vicente, Jonathan J. Taliercio, John O’Toole, Emilio D. Poggio, Leslie Cooperman, Stacey E. Jolly, Leal Herlitz, Jane Nguyen, Ellen L. Palmer, Dianna Sendrey, Kassandra Spates-Harden, Paul S. Appelbaum, Jonathan Barasch, Andrew S. Bomback, Vivette D. D’Agati, Karla Mehl, Pietro A. Canetta, Ning Shang, Olivia Balderes, Satoru Kudose, Laura Barisoni, Theodore Alexandrov, Ying‐Hua Cheng, Kenneth W. Dunn, Katherine J. Kelly, Timothy A. Sutton, Yumeng Wen, Celia P. Corona-Villalobos, Steven Menez, Avi Z. Rosenberg, Mohammed Atta, Camille Johansen, Jennifer K. Sun, Neil Roy, Mark Williams, Evren U. Azeloglu, Cijang He, Ravi Iyengar, Jens Hansen, Yuguang Xiong, Brad H. Rovin, Samir V. Parikh, Sethu M. Madhavan, Christopher Anderton, Ljiljana Paša‐Tolić and 70 more - Nature 2023 cited by 693

  3. Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach

    Authors: , , , , - American Journal of Nephrology 2013 cited by 4,380

  4. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 973

  5. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 438

  6. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege - Kidney International 2021 cited by 791

  7. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

    Authors: , , , , , , , , , , , - Arthritis & Rheumatism 2012 cited by 1,437

  8. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , - The Lancet 2021 cited by 593

  9. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Muh Geot Wong, Vlado Perkovic, Isabella Abbasciano, Catarina Abrantes, Simone Accarino, Sharon G. Adler, Annika Adoberg, Rouzbeh Afsari, Syeda B. Ahmad, Jafar Ahmed, Wooin Ahn, Bamidele Ajayi, Dariusz Aksamit, Saif Al‐Chalabi, É. Alamartine, Bassam Alchi, Mohammad Ali, Roberta Aliotta, Salem Almaani, Catarina Almeida, Edgar Almeida, Francisco de la Prada Álvarez, Patrícia Marques‐Alves, Francesca Annese, Gerald B. Appel, Gerald Appel, Maria Arena, Marta Calvo Arevalo, Dariush Arfaania, Carlos Arias, Emma Calatayud Aristoy, Eglė Ašakienė, Sarah Ashley, Ali Assefi, Alba Atenza, Asta Auerbach, Hanna Augustyniak‐Bartosik, Hanna Augustyniak-Bartosik, Jonathan Ayling-Smith, Isabelle Ayoub, Isabelle Ayoub, Rocco Baccaro, Asha Bailey, Bruce Baker, Saravanan Balamuthusamy, José Ballarín, Rui Barata, Jerko Barbić, Dunja Barisic, Jonathan Barratt, José C. Barreto, Clara Barrios, Mirco Belingheri, Anna Benesova, Ana Ávila Bernabéu, Wanja Bernhardt, Shamik Bhadra, Luigi Biancone, Anne Blanchard, Elena Boaglio, Davide Bolignano, Andrew S. Bomback, Gustavo Andres Useche Bonilla, M Bordoli, Bhadran Bose, Neil Boudville, Donald Brandon, Donald Brandon, Karen Brown, C Broyet and 634 more - The Lancet 2023 cited by 267

  10. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

    Authors: , , , , , , , , , , , - The Lancet 2023 cited by 289

  11. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

    Authors: , , , , , - Kidney International 2024 cited by 418

  12. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal

    Authors: , , , , , , , , , - Annals of the Rheumatic Diseases 2019 cited by 433

  13. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jay Radhakrishnan, Heather N. Reich, Samir V. Parikh, Debbie S. Gipson, Dominic K. Lee, Bruno R. da Costa, Peter Jüni, Daniel Cattran - New England Journal of Medicine 2019 cited by 600

  14. Update on Lupus Nephritis: Core Curriculum 2020

    Authors: , , , - American Journal of Kidney Diseases 2020 cited by 489

  15. Update on Lupus Nephritis

    Authors: , , - Clinical Journal of the American Society of Nephrology 2016 cited by 918

  16. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mai Rosenberg, Brad H. Rovin, Sydney Tang, Vladmir Tesar, Muh Geot Wong, Bhadran Bose, Muralikrishna Gangadharan, Stephen P. McDonald, Chen Au Peh, Sadia Jahan, Chii Yeap, Philip A. Clayton, Georgina Irish, Nikhil Thyagarajan, Peter Hollett, Rathika Krishnasamy, Robert J. Carroll, Shilpanjali Jesudason, Susan Crail, Toby Coates, Jane Waugh, Euan Noble, Kumaradevan Mahadevan, Victoria Campbell, Tania Salehi, Wai H. Lim, Neil Boudville, Aron Chakera, Doris Chan, Anoushka Krishnan, Yusuf Eqbal, Alastair Gillies, Eswari Vilayur, Thida Maung Myint, Nicholas A. Gray, Jane Waugh, Euan Noble, Melissa S Cheetham, Yusuf Eqbal, Peter Hollett, Rathika Krishnasamy, Kumaradevan Mahadevan, Victoria Campbell, Carol A. Pollock, Bruce A. Cooper, Amanda Mather, Sarah Roxburgh, Yvonne Shen, Stefanie Stangenberg, Amanda Siriwardana, Emma O’Lone, Susan Wan, Brendon L. Neuen, Jeffrey T. Ha, Dana Kim, Lauren Heath, Arunima Jain, Elaine Phua, Li Yan, M. W. Gallagher, Meg Jardine, Angus Ritchie, Mona Razavian, Celine Foote, Roger Wyndham, Shaundeep Sen, Zoltán Endre, Jonathan Erlich, Mangalee Fernando, Kenneth Yong and 631 more - The Lancet 2023 cited by 215

  17. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

    Authors: , , , , , , , , , , , , , , , , - Clinical Journal of the American Society of Nephrology 2019 cited by 288

  18. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Paula Dionisi, Jessica Ryan, Nigel D. Toussaint, Grant Luxton, Chen Au Peh, Vicki Levidiotis, Ross S. Francis, Richard Phoon, Elena Fedosiuk, D.M. Toropilov Toropilov, R. E. Yakubtsevich, Elena Mikhailova, Christophe Bovy, Nathalie Demoulin, Jean‐Michel Hougardy, Bart Maes, Marijn M. Speeckaert, Louis‐Philippe Laurin, Sean Barbour, Mélanie Masse, Michelle Hladunewich, Heather N. Reich, Serge Cournoyer, Karthik Tennankore, Sean Barbour, Jicheng Lv, Zhangsuo Liu, Caili Wang, Shaomei Li, Qun Luo, Zhaohui Ni, Tiekun Yan, Ping Fu, Hong Cheng, Bi‐Cheng Liu, Wanhong Lu, Jianqin Wang, Qinkai Chen, D. Wang, Zuying Xiong, Menghua Chen, Yan Xu, Jiali Wei, Pearl Pai, Lianhua Chen, Jitka Řehořová, Dita Maixnerová, Roman Šafránek, Ivan Rychlík, M Hrubý, Satu Mäkelä, Kati Vääräniemi, Fernanda Ortiz, É. Alamartine, Maïté Daroux, C. Cartery, François Vrtovsnik, Jean‐Emmanuel Serre, Eleni Stamellou, Volker Vielhauer, Christian Hugo, Klemens Budde, Britta Otte, Martin Nitschke, Evangelia Ntounousi, Ioannis Boletis, Αikaterini Papagianni, Dimitrios Goumenos, Kostas Stylianou, Synodi Zermpala and 59 more - Kidney International 2022 cited by 215

  19. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

    Authors: , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 194

  20. A reference tissue atlas for the human kidney

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kun Zhang, Jonathan Himmelfarb, Brad H. Rovin, Tarek M. El‐Achkar, Zoltán Lászik, John Cijiang He, Pierre C. Dagher, M. Todd Valerius, Sanjay Jain, Lisa M. Satlin, Olga G. Troyanskaya, Matthias Kretzler, Ravi Iyengar, Evren U. Azeloglu, Kidney Precision Medicine Project - Science Advances 2022 cited by 172

  21. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

    Authors: , , , , , , , , , , , , , , , - Kidney International 2023 cited by 121

  22. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

    Authors: , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2016 cited by 288

  23. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis

    Authors: , , , , , , , , , , , , - Kidney International 2021 cited by 198

  24. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 105